https://www.taxtmi.com/news?id=56868 Advanced CAR-T cell therapy with the India-developed NexCAR19 was given to a 31-year-old with high-risk Pre-B Acute Lymphoblastic Leukemia after lymphodepleting preconditioning with fludarabine and cyclophosphamide; the infusion produced manageable fever and fatigue and no neurotoxicity, reported as the hospital's first adult leukemia CAR-T case and as evidence of local manufacture and feasible delivery of personalized cellular therapy in an Indian clinical setting. en-us Thu, 25 Sep 2025 11:31:03 +0530 Thu, 25 Sep 2025 11:31:03 +0530 TaxTMI RSS Generator https://www.taxtmi.com/news?id=56868 Advanced CAR-T cell therapy with the India-developed NexCAR19 was given to a 31-year-old with high-risk Pre-B Acute Lymphoblastic Leukemia after lymphodepleting preconditioning with fludarabine and cyclophosphamide; the infusion produced manageable fever and fatigue and no neurotoxicity, reported as the hospital's first adult leukemia CAR-T case and as evidence of local manufacture and feasible delivery of personalized cellular therapy in an Indian clinical setting. News - Thu, 25 Sep 2025 11:31:03 +0530 https://www.taxtmi.com/news?id=56868